Pharma Focus Asia

WuXi Biologics

WuXi Biologics

WuXi XDC Research Platform & Capability for Integrated Bioconjugation Discovery Services

Since the year of 2000, there’re 13 ADCs on the market and 9 of them were approved in the last three years. The enthusiasm of pharmaceutical and biotechnology companies for the research and development of ADC has been increasing. How to quickly complete the early development of ADC through differentiation strategy has become an important link for companies to focus on competition. WuXi XDC has established a one-stop discovery service platform, covering from protein/antibody generation, linker-payload synthesis, bioconjugation, in vitro/in vivo functional studies and developability study, for bioconjugate drugs to meet the early research needs of the customers.


  • Scientists

  • Bioprocess Engineers

  • Bioproduction Engineers

  • Process Development Engineers

  • Process Development Managers

  • Consultants R&D Scientists

무석 바이오로직스

Register for free to get video access

Speaker :


Dr. Jiawei Lu

Director of Bioconjugates, Discovery Services, WuXi XDC

About - Dr. Jiawei Lu

Dr. Jiawei Lu , director of Bioconjugates Discovery Services from WuXi XDC, has ten years of experiences in bioconjugation. Now he is responsible of building a first-class discovery services empower platform of conjugated drugs. His team has extensive experiences in conjugation, purification, and characterization of various types of conjugates, including ADC, PEGylated protein, bispecific antibodies, Antibody-Oligonucleotide conjugates, Antibody-Chelator conjugates, 2nd antibody, etc. In the past 8 years, his team has built long-term collaboration with numerous customers and has successfully advanced plenty of lead molecules from discovery stage to CMC stage.